ABCG2 and breast cancer: In vitro dual inhibition of ABCC1 and ABCG2-mediated daunorubicin and mitoxantrone efflux was demonstrated by talazoparib, a TK inhibitor used in metastatic BCRA1/2-mutated breast cancer [118].